stockrow
Friday 6 November 2026
Export BTCY’s income statement to Excel — free account
Biotricity Inc.
BTCY Healthcare Medical Devices
Biotricity Inc.’s revenue for fiscal 2026 (year ended March 2026) was $16.0 million, up 16.0% from fiscal 2025.
- Revenue
- +10.4%
- EPS
- −66.7%
- Free cash flow
- +235.8%
- Total debt
- +3.48%
Quarter to June 2026, against a year earlier
0.06
0.01
+20.00%
Follow BTCY
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.17 | 0.41 | 0.54 | 0.94 | |
P/FCF ratio |
21.03 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
5.46 | (313.54) | (11.18) | 34.14 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.77 | 2.07 | 2.24 | 2.62 | |
EV/EBITDA |
12.19 | 13.54 | 38.67 | 113.61 | |
EV/Operating CF |
179.35 | (45.99) | (31.46) | (88.56) | |
EV/FCF |
219.90 | (44.16) | (30.63) | (83.02) | |
Quick Ratio |
0.08 | 0.08 | 0.08 | 0.10 | |
Current Ratio |
0.15 | 0.16 | 0.21 | 0.23 | |
Net Debt/EBITDA |
54.32 | 47.60 | 27.06 | 69.21 | |
Debt/Assets |
442.89% | 413.65% | 466.84% | 406.16% | |
Debt/Equity |
(0.75) | (0.77) | (0.78) | (0.77) | |
Asset Turnover |
2.72 | 2.65 | 2.65 | 2.60 | |
Operating CF/Net income |
(0.47) | 0.05 | 0.64 | (0.54) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.19 | 0.83 | 0.54 | 0.32 | |
Research and Development Expense of Revenue |
15.74% | 19.80% | 15.64% | 15.51% | |
Selling, General and Administrative Expense of Revenue |
63.11% | 43.82% | 54.84% | 59.32% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.95% | (0.72%) | 1.20% | 0.15% | |
Graham Net Nets |
(12.93) | (5.38) | (4.22) | (2.41) | |
Graham Number |
2.27 | 1.85 | 2.11 | 2.19 | |
Earnings Yield |
(116.67%) | (50.00%) | (53.33%) | (32.08%) | |
Free Cash Flow Yield |
4.76% | (11.43%) | (13.64%) | (3.36%) | |
Revenue per Share |
0.19 | 0.16 | 0.14 | 0.15 | |
Operating CF per Share |
0.02 | 0.00 | (0.03) | 0.02 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.02 | 0.00 | (0.03) | 0.02 | |
Cash per Share |
0.02 | 0.01 | 0.01 | 0.01 | |
Shareholders Equity per Share |
(1.53) | (1.27) | (1.24) | (1.25) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.53) | (1.27) | (1.24) | (1.25) | |
Free Cash Flow |
0.51 | (0.02) | (0.74) | 0.42 | |
Working Capital |
(31.75) | (31.28) | (18.82) | (18.08) | |
Net Current Asset Value |
(35.83) | (35.27) | (34.94) | (34.20) | |
EV/EBIT |
18.49 | 19.55 | 244.99 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
1.77 | 3.87 | 58.66 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.13 | 2.30 | 1.41 | 1.80 | |
Average Payables |
8.58 | 8.32 | 8.47 | 8.48 | |
Average Inventory |
1.60 | 1.45 | 1.77 | 2.04 | |
Average Assets |
6.03 | 6.04 | 5.84 | 5.81 | |
Average Common Equity |
(35.32) | (33.35) | (33.09) | (32.29) |
Columns are period end dates · fundamentals updated 2 Nov 2026